Búsqueda | Portal de Búsqueda de la BVS España

1.

Dexamethasone as a partner of isatuximab.

Mateos, M V; González-Calle, V.

Blood; 137(9): 1133-1134, 2021 03 04.

Artículo en Inglés | MEDLINE | ID: mdl-33661291

2.

Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322].

Dimopoulos, M A; Moreau, P; Terpos, E; Mateos, M V; Zweegman, S; Cook, G; Delforge, M; Hájek, R; Schjesvold, F; Cavo, M; Goldschmidt, H; Facon, T; Einsele, H; Boccadoro, M; San-Miguel, J; Sonneveld, P; Mey, U.

Ann Oncol; 33(1): 117, 2022 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-34857439

3.

Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117].

Dimopoulos, M A; Moreau, P; Terpos, E; Mateos, M V; Zweegman, S; Cook, G; Delforge, M; Hájek, R; Schjesvold, F; Cavo, M; Goldschmidt, H; Facon, T; Einsele, H; Boccadoro, M; San-Miguel, J; Sonneveld, P; Mey, U.

Ann Oncol; 33(9): 988, 2022 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-35810138

4.

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Dimopoulos, M A; Moreau, P; Terpos, E; Mateos, M V; Zweegman, S; Cook, G; Delforge, M; Hájek, R; Schjesvold, F; Cavo, M; Goldschmidt, H; Facon, T; Einsele, H; Boccadoro, M; San-Miguel, J; Sonneveld, P; Mey, U.

Ann Oncol; 32(3): 309-322, 2021 03.

Artículo en Inglés | MEDLINE | ID: mdl-33549387

5.

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.

Medina-Herrera, A; Vazquez, I; Cuenca, I; Rosa-Rosa, J M; Ariceta, B; Jimenez, C; Fernandez-Mercado, M; Larrayoz, M J; Gutierrez, N C; Fernandez-Guijarro, M; Gonzalez-Calle, V; Rodriguez-Otero, P; Oriol, A; Rosiñol, L; Alegre, A; Escalante, F; De La Rubia, J; Teruel, A I; De Arriba, F; Hernandez, M T; Lopez-Jimenez, J; Ocio, E M; Puig, N; Paiva, B; Lahuerta, J J; Bladé, J; San Miguel, J F; Mateos, M V; Martinez-Lopez, J; Calasanz, M J; Garcia-Sanz, R.

Blood Cancer J; 14(1): 74, 2024 Apr 29.

Artículo en Inglés | MEDLINE | ID: mdl-38684670

6.

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Moreau, P; San Miguel, J; Sonneveld, P; Mateos, M V; Zamagni, E; Avet-Loiseau, H; Hajek, R; Dimopoulos, M A; Ludwig, H; Einsele, H; Zweegman, S; Facon, T; Cavo, M; Terpos, E; Goldschmidt, H; Attal, M; Buske, C.

Ann Oncol; 28(suppl_4): iv52-iv61, 2017 Jul 01.

Artículo en Inglés | MEDLINE | ID: mdl-28453614

7.

Selective localization of phosphatidylcholine-derived signaling in detergent-resistant membranes from synaptic endings.

Mateos, M V; Salvador, G A; Giusto, N M.

Biochim Biophys Acta; 1798(3): 624-36, 2010 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-20026046

8.

Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation.

Caballero-Velázquez, T; Calderón-Cabrera, C; López-Corral, L; Puig, N; Marquez-Malaver, F; Pérez-López, E; García-Calderón, C; Rosso-Fernández, C M; Caballero Barrigón, D; Martín, J; Mateos, M V; San Miguel, J; Pérez-Simón, J A.

Bone Marrow Transplant; 55(2): 419-430, 2020 02.

Artículo en Inglés | MEDLINE | ID: mdl-31551517

9.

Inverse Probability of Censoring Weighted Analysis to Adjust the Treatment Effect on Overall Survival for Subsequent Therapy: A Case Study in a Clinical Trial in Multiple Myeloma.

Thilakarathne, P; Palumbo, A; Diels, J; Delforge, M; van Sanden, S; Mateos, M V; Chirita, O; Dimopoulos, M A; van de Velde, H; San Miguel, J F.

Value Health; 17(7): A546, 2014 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-27201769

10.

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Chim, C S; Kumar, S K; Orlowski, R Z; Cook, G; Richardson, P G; Gertz, M A; Giralt, S; Mateos, M V; Leleu, X; Anderson, K C.

Leukemia; 33(4): 1058-1059, 2019 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-30842604

11.

Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis.

Gutiérrez, N C; Castellanos, M V; Martín, M L; Mateos, M V; Hernández, J M; Fernández, M; Carrera, D; Rosiñol, L; Ribera, J M; Ojanguren, J M; Palomera, L; Gardella, S; Escoda, L; Hernández-Boluda, J C; Bello, J L; de la Rubia, J; Lahuerta, J J; San Miguel, J F.

Leukemia; 21(1): 143-50, 2007 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-17024116

12.

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Chim, C S; Kumar, S K; Orlowski, R Z; Cook, G; Richardson, P G; Gertz, M A; Giralt, S; Mateos, M V; Leleu, X; Anderson, K C.

Leukemia; 32(2): 252-262, 2018 02.

Artículo en Inglés | MEDLINE | ID: mdl-29257139

13.

Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials.

Arana, P; Paiva, B; Cedena, M-T; Puig, N; Cordon, L; Vidriales, M-B; Gutierrez, N C; Chiodi, F; Burgos, L; Anglada, L-L; Martinez-Lopez, J; Hernandez, M-T; Teruel, A-I; Gironella, M; Echeveste, M-A; Rosiñol, L; Martinez, R; Oriol, A; De la Rubia, J; Orfao, A; Blade, J; Lahuerta, J-J; Mateos, M-V; San Miguel, J-F.

Leukemia; 32(4): 971-978, 2018 04.

Artículo en Inglés | MEDLINE | ID: mdl-29099494

14.

Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC).

Sanoja-Flores, L; Flores-Montero, J; Garcés, J J; Paiva, B; Puig, N; García-Mateo, A; García-Sánchez, O; Corral-Mateos, A; Burgos, L; Blanco, E; Hernández-Martín, J; Pontes, R; Díez-Campelo, M; Millacoy, P; Rodríguez-Otero, P; Prosper, F; Merino, J; Vidriales, M B; García-Sanz, R; Romero, A; Palomera, L; Ríos-Tamayo, R; Pérez-Andrés, M; Blanco, J F; González, M; van Dongen, J J M; Durie, B; Mateos, M V; San-Miguel, J; Orfao, A.

Blood Cancer J; 8(12): 117, 2018 11 19.

Artículo en Inglés | MEDLINE | ID: mdl-30455467

15.

Bortezomib in multiple myeloma.

Mateos, M V; San Miguel, J F.

Best Pract Res Clin Haematol; 20(4): 701-15, 2007 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-18070714

16.

Hyperhomocysteinemia is a risk factor of recurrent coronary event in young patients irrespective to the MTHFR C677T polymorphism.

Gonzalez-Porras, J R; Martin-Herrero, F; Garcia-Sanz, R; Lopez, M L; Balanzategui, A; Mateos, M V; Pavon, P; Gonzalez, M; Alberca, I; San Miguel, J F.

Thromb Res; 119(6): 691-8, 2007.

Artículo en Inglés | MEDLINE | ID: mdl-17005242

17.

Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes.

Hari, P; Mateos, M-V; Abonour, R; Knop, S; Bensinger, W; Ludwig, H; Song, K; Hajek, R; Moreau, P; Siegel, D S; Feng, S; Obreja, M; Aggarwal, S K; Iskander, K; Goldschmidt, H.

Leukemia; 31(12): 2630-2641, 2017 12.

Artículo en Inglés | MEDLINE | ID: mdl-28439109

18.

Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma.

Fernández de Larrea, C; Dávila, J; Isola, I; Ocio, E M; Rosiñol, L; García-Sanz, R; Cibeira, M T; Tovar, N; Rovira, M; Mateos, M V; Miguel, J S; Bladé, J.

Bone Marrow Transplant; 52(4): 567-569, 2017 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-27869809

19.

Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network.

Ludwig, H; Delforge, M; Facon, T; Einsele, H; Gay, F; Moreau, P; Avet-Loiseau, H; Boccadoro, M; Hajek, R; Mohty, M; Cavo, M; Dimopoulos, M A; San-Miguel, J F; Terpos, E; Zweegman, S; Garderet, L; Mateos, M-V; Cook, G; Leleu, X; Goldschmidt, H; Jackson, G; Kaiser, M; Weisel, K; van de Donk, N W C J; Waage, A; Beksac, M; Mellqvist, U H; Engelhardt, M; Caers, J; Driessen, C; Sonneveld, P.

Leukemia; 2017 Dec 18.

Artículo en Inglés | MEDLINE | ID: mdl-29251284

20.

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.

Flores-Montero, J; Sanoja-Flores, L; Paiva, B; Puig, N; García-Sánchez, O; Böttcher, S; van der Velden, V H J; Pérez-Morán, J-J; Vidriales, M-B; García-Sanz, R; Jimenez, C; González, M; Martínez-López, J; Corral-Mateos, A; Grigore, G-E; Fluxá, R; Pontes, R; Caetano, J; Sedek, L; Del Cañizo, M-C; Bladé, J; Lahuerta, J-J; Aguilar, C; Bárez, A; García-Mateo, A; Labrador, J; Leoz, P; Aguilera-Sanz, C; San-Miguel, J; Mateos, M-V; Durie, B; van Dongen, J J M; Orfao, A.

Leukemia; 31(10): 2094-2103, 2017 10.

Artículo en Inglés | MEDLINE | ID: mdl-28104919

Portal de Búsqueda de la BVS España

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Dexamethasone as a partner of isatuximab.

Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322].

Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117].

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Selective localization of phosphatidylcholine-derived signaling in detergent-resistant membranes from synaptic endings.

Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation.

Inverse Probability of Censoring Weighted Analysis to Adjust the Treatment Effect on Overall Survival for Subsequent Therapy: A Case Study in a Clinical Trial in Multiple Myeloma.

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis.

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials.

Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC).

Bortezomib in multiple myeloma.

Hyperhomocysteinemia is a risk factor of recurrent coronary event in young patients irrespective to the MTHFR C677T polymorphism.

Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes.

Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma.

Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network.

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.